Roche obtained 510 approval from the US Food and Drug Administration, and its novel COBAS® eplex respiratory pathogen test combination3 was approved, enabling the laboratory to tailor respiratory testing plans according to local patient needs.

Roche obtained 510 approval from the US Food and Drug Administration, and its novel COBAS® eplex respiratory pathogen test combination3 was approved, enabling the laboratory to tailor respiratory testing plans according to local patient needs.